Unit News
Showing items
through of articles.
-
WVU Rockefeller Neuroscience Institute first in U.S. to use deep brain stimulation to fight opioid addiction
Tuesday, November 5, 2019
The West Virginia University Rockefeller Neuroscience Institute and WVU Medicine, today (Nov. 5) announced the launch of a first-in-the-U.S. clinical trial using deep brain stimulation for patients suffering from treatment-resistant opioid use disorder. -
WVU in the News: Dr. Umer Najib recognized by American Academy of Neurology
Monday, November 4, 2019
Umer Najib, M.D., an assistant professor and program director of the Headache Medicine Fellowship program at J.W. Ruby Memorial Hospital and the West Virginia University Rockefeller Neuroscience Institute was recently featured in the October 2019 edition of the American Academy of Neurology newsletter.Read WVU in the News: Dr. Umer Najib recognized by American Academy of Neurology full story
-
WVU Cancer Institute Annual Meeting and Hardesty Lecture
Friday, November 1, 2019
The WVU Cancer Institute (WVUCI) is sponsoring the second Annual WVUCI Scientific Meeting on Nov. 22, 2019, at the Erickson Alumni Center. This is a half-day event with scientific sessions that include outside speakers, as well as reports from selected WVUCI faculty members highlighting their basic, clinical and population research.Read WVU Cancer Institute Annual Meeting and Hardesty Lecture full story
-
Free Dual Opioid Training Sessions Available
Thursday, October 31, 2019
For area healthcare and social workers, physicians, physician assistants and nurse practitioners battling the opioid epidemic:, a free dual course is available Nov. 15, 2019, at the United Hospital Center.Read Free Dual Opioid Training Sessions Available full story
-
WVU researchers awarded joint Small Business Technology Transfer Grant for treatment of acute arthritis
Tuesday, October 29, 2019
The National Institutes of Health has just awarded a new Small Business Technology Transfer (STTR) grant jointly to a small West Virginia-based business ExesaLibero Pharma and WVU, as its primary academic partner. This grant is awarded in two separate phases, Phase 1 is for six months and after satisfying specified milestones, Phase 2 is awarded for an additional two years. These grants are awarded to the small business company that then subcontracts with WVU and other entities to conduct portions of the research work.
